XML 29 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Major Customers and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2015
Risks and Uncertainties [Abstract]  
Major Customers and Concentration of Credit Risk
Major Customers and Concentration of Credit Risk
 
Customer
2015
 
% of Total
Revenue
 
2014
 
% of Total
Revenue
 
2013
 
% of Total
Revenue
MedImmune
$
16,037,731

 
40
%
 
$
—

 
—
%
 
$
—

 
—
%
DARPA
11,582,623

 
28

 
123,605

 
1

 
—

 
—

Roche
10,778,688

 
27

 
7,357,346

 
70

 
9,181,759

 
68

NIAID
901,475

 
2

 
1,229,084

 
12

 
2,090,939

 
16

GeneOne (affiliated entity)
450,000

 
1

 
479,464

 
5

 
425,000

 
3

All other
821,594

 
2

 
1,267,267

 
12

 
1,769,648

 
13

Total Revenue
$
40,572,111

 
100
%
 
$
10,456,766

 
100
%
 
$
13,467,346

 
100
%


During the years ended December 31, 2015, 2014 and 2013, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December 31, 2015, $4.0 million or 54%, $1.6 million or 22% and $1.5 million or 20% of accounts receivable was attributed to DARPA, Roche and MedImmune, respectively. As of December 31, 2014, $2.3 million or 82% and $190,000 or 7% of accounts receivable was attributed to Roche and the NIAID, respectively.
There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.